The Temerty Faculty of Medicine EIR program supports researchers to commercialize their work by connecting them with leaders in business and entrepreneurship.
As identified in the Strategic Plan and generously supported by the Temerty Foundation, the Faculty is pleased to announce the launch of its Entrepreneur in Residence (EiR) program.
The EiR program supports researchers with commercialization goals and prior experience in conducting commercialization activities. These activities may include: technology licencing, start-up creation or participating in research commercialization training courses, programs and events.
Specifically, the EIR program connects selected researchers and their commercialization teams with individuals external to the University with experience in areas such as:
Entrepreneurs-in-Residence are experienced leaders with the expertise, resources and networks to help accelerate the commercialization of research-based start-ups. These EiRs will work with program participants one-on-one to share their experience and help researchers develop and execute a robust commercialization plan.
Dr. MARTIN CROTEAU
An expert in the field of early-stage technology startups with more than 20 years of experience as a founder, an investor, an advisor and an academic. Martin was on the founding team of Slipstream Data, which was acquired by Blackberry. He is currently an active angel investor, an Entrepreneur-in-Residence with several incubators, and a Lecturer in entrepreneurship at Ryerson University and the University of Toronto. Martin was previously the Director of Academic Entrepreneurship at the Ontario Centres of Excellence, where he was responsible for rolling out a network of 59 campus-linked business accelerators and incubators. He was also the founder and Executive Director of Spark Centre, and co-founder and board member of the Spark Angel Investment Network.
Areas of Expertise: Commercialization strategy, Early stage funding
Passionate about a better future, experienced leader, mentor and manager in the health sector focused on innovation, business and technology. Senior management and director positions in public and private sectors. Established and delivered incubation models, Led product from inception to market. Very target oriented performance, highly motivated and a team player. International experience in Israel, China, Europe and North America.
Technical, investment, management expertise.
Areas of expertise: Health innovation, Incubation, Photonics, Business development, Investment, Semiconductors, board positions, Algorithms, Aging technologies
John Haslam is the President and Founder of HEARD Consulting International, specializing in assisting companies with Rare Disease Medicines build winning go to market strategies in order to bring their innovation to Canadian patients. As Canadian General Manager, John built and led the Canadian operations for 2 major Rare Disease companies (Alexion & Horizon Therapeutics) over the past 12 years generating combined annual sales of $150M annually. Prior to that John worked in senior commercial roles at major pharmaceutical organizations within the industry including Bayer, Roche and Biogen. John obtained his B.Sc. in Microbiology from University of Toronto and his M.B.A. from McMaster DeGroote School of Business. John is a Board Member of Life Sciences Ontario, founding member of the Rare Innovators group and past Board Member for Innovative Medicines Canada and Biotech Canada. John has been honoured with the Canadian Organization for Rare Disorders (CORD) corporate partner award and was inducted into the Canadian Pharmaceutical Marketing Hall of Fame in October of 2015.
Areas of expertise: Health innovation, Go-to-market strategies, Rare disease medicines
A serial entrepreneur, angel investor and cofounder in four companies with successful exits (2X public), Vigen has accrued deep expertise in the development of early-stage ventures in the biopharmaceutical, medical device, health and med-tech areas. He is passionate about early-stage research innovations that require guidance in product development planning, IP strategy, market analysis, business strategy, go to market strategy, funding/venture financing and corporate development. Vigen has deep network of academic and corporate partners that augment, de-risk and accelerate the development of promising ventures.
In the past 20 years, Vigen has mentored over 1000 entrepreneurs as EIR and Mentor at several Canadian incubator and accelerator hubs from coast to coast. He is also a board member and advisor on several public and private organizations such as McMaster Innovation Park, University of Toronto ICUBE, and Protagenic Therapeutics (NASDAQ: PTIX).
Areas of Expertise: Biopharmaceuticals, Angel Investors, Venture and Product Development, Strategy.
Sohaib has focused his career on improving clinical outcomes and increasing access to healthcare for patients. He is a doctor and clinical researcher by trade. He’s recently transitioned to venture capital where he advises multiple stakeholders to invest and scale innovation in healthcare.
He has experience in managing investments alongside private equity, family offices, venture funds, and incubators. He works closely with several start-up by serving as their Chief Medical Officer and board member. He also has an academic appointment at Women’s College Hospital where he helps digital healthcare companies gain market adoption. Sohaib holds a B.ScH from Queen’s University, degrees in Medicine, Surgery & Obstetrics from the Royal College of Surgeons in Ireland, and Executive Education Certification in Digital Health from Harvard Medical School.
Sam is presently a Toronto-based research and development consultant for BioNTech, a global biopharmaceutical company. Prior to this, Sam was based in New York City as a founding partner and program director of IndieBio New York. IndieBio is an accelerator for life science start-up companies. Its portfolio of invested companies is valued at over US$3 billion. Prior to that, Sam spent eight years in Princeton, New Jersey as head of external R&D for Dr. Reddy’s Laboratories, the world’s tenth largest generic pharmaceutical company, and also led U.S. health tech investments for its corporate venture arm. From 2001 to 2007, Sam was Senior Director of Research for NPS Pharmaceuticals, which was acquired by Shire for US$5.2 billion for its successful development of a drug invented by a Toronto physician-scientist. Sam was also a consultant for a Toronto cardiologist to help him advance his drug invention from animal studies to First-In-Human studies and to raise first round financing for his company. Sam obtained his Ph.D. in chemistry from the University of Toronto. During that time, he co-founded a private vocational school teaching students GMP pharmaceutical manufacturing. The school is still operating today, graduating 200 students per year. Sam’s expertise is biopharmaceuticals and health tech.
Dr. Chan is a lawyer, scientist, educator, and startup mentor.
Gabriella’s Ph.D. work focused on molecular diagnostics for infectious diseases, particularly malaria and SARS-CoV, supported by the University of Toronto’s prestigious Connaught Scholarship and a Canadian Institutes of Health Research (CIHR) Doctoral Research Award. As a post-doctoral researcher, she participated in the developed of nanotechnology-based hand-held diagnostic device.
While working for a biotechnology startup and liaising with the company’s lawyers in her role as an Intellectual Property and Technology Manager after completing her scientific training, Gabriella identified a gap. Scientists don’t speak legalize and lawyers don’t always appreciate the science behind their clients’ products. To bridge that gap, Gabriella obtained a law degree from Osgoode Hall Law School with a focus in business and intellectual property and trained at a national Bay Street law firm in Toronto. Gabriella continued to hone her legal skills in her role as Vice President of Legal Affairs at another Toronto-area nanotechnology startup and later founded Yocto Law® Professional Corporation, a boutique law firm that advises startups and other stakeholders in the life sciences and health technology sectors.
The principal applicant must hold a faculty appointment within the Temerty Faculty of Medicine at the time of submission and be able to demonstrate their commitment to commercialization.
Successful applicants will be awarded up to a total of 100 hours of support with up to 3 EIRs who offer different resources and expertise over a 20-week period. Faculty have an opportunity to request EIRs that they believe will help them address a specific challenge they are facing. Faculty are able to request additional hours of support following the first 100 hours if they are meeting milestones and the EIR(s) remain committed to the project.
The EIR program is a staged process to ensure only faculty that will benefit from the program are selected for support:
Faculty apply for EIR support via the online application form. The initial proposal review is conducted by operational staff to ensure the application is complete and meets the requirements of the program. If necessary, further clarification and discussion with applicants will occur. If approved for eligibility, the complete application package is shared with the adjudication committee
At this stage, the adjudication committee evaluates each proposal and assesses its merits and alignment to the EIR program.
The EIR program is intended to support faculty who have experience with commercialization projects, demonstrate an entrepreneurial mindset and have validated the basic market need of their technology.
Applications to this program are adjudicated based on the following criteria:
The EIR program staff is responsible for the orientation of the AC members with respect to rules and procedures to evaluate the proposals.
The proposals rated most highly by the AC will be selected for EIR support. The AC is then responsible for assigning the most suitable EIRs from its pool to the awarded projects.
Selected applicants will be informed of their acceptance into the program and the EIRs identified to assist them. Faculty have the option to accept, pending acceptance of the EIRs. Program staff will confirm availability of EIRs and finalize program acceptance. Program staff will also work with faculty to recruit any requested EIR. This process may be iterative based on EIR availability.
Once all participants have accepted, information packages will be sent to both faculty and EIRs to help them learn more about one another and to get the most out of the program.
To initiate the engagement, it is recommended that a 60-min introductory call with research team and EIR(s) be scheduled. This meeting allows the group to meet each other, review the goals of the next 16 weeks, and determine an effective working process going forward. The faculty member will be responsible for arranging meetings and ensuring that the EIR program is helping them meet their goals.
Following the completion of the program both the EIRs and faculty member will be asked to complete a simple (1pg) reflection on how the EIR program helped them meet their goals and how it can be improved. This form will be supplied by program staff and should be completed within 60 days of the conclusion of the engagement.
Jarrod Ladouceur, Industrial Partnership Officer at Jarrod.email@example.com